Use of psychotropic drugs in treatment of methadone maintained narcotic addicts.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D008691:Methadone / Q000008:administration & dosage / Q000627:therapeutic use*; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D011957:Receptors, Opioid / Q000187:drug effects; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D007319:Sleep Initiation and Maintenance Disorders / Q000150:complications / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000150:complications / Q000534:rehabilitation*
D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D008996:Monoamine Oxidase Inhibitors; D011619:Psychotropic Drugs; D011957:Receptors, Opioid; D001569:Benzodiazepines; D008094:Lithium; D008691:Methadone